Cidara Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue during the quarter, a decrease from $1.3 million in collaboration revenue reported in the same period last year. The absence of revenue is attributed to the termination of the Janssen Collaboration Agreement in April 2024, which previously generated income from research and development services. The company’s net loss for the quarter was $83.2 million, compared to a loss of $16.0 million in the prior year, reflecting increased operational costs primarily related to research and development activities.
Total operating expenses surged to $88.6 million for the third quarter of 2025, up from $17.4 million in the same quarter of 2024. This increase was driven by a $45 million expense related to acquired in-process research and development under the Janssen License Agreement, as well as higher research and development costs associated with the ongoing clinical trials for its lead product candidate, CD388. General and administrative expenses also rose to $8.1 million from $5.0 million, largely due to increased personnel costs and stock-based compensation.
On the operational front, Cidara has made strategic advancements with its CD388 program, which is designed for the prevention and treatment of influenza. The company initiated a Phase 3 clinical trial, known as the ANCHOR study, in September 2025, following positive results from a Phase 2b trial. The ANCHOR study aims to evaluate the safety and efficacy of a single 450 mg dose of CD388 in a larger population, including high-risk groups. The company has also entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA), which could provide up to $339.2 million in funding to support the development of CD388.
As of September 30, 2025, Cidara reported total assets of $518.7 million, a substantial increase from $214.8 million at the end of 2024, primarily due to proceeds from recent financing activities. The company raised approximately $376.9 million from a public offering in June 2025 and an additional $4.1 million from an at-the-market offering. Cidara's cash, cash equivalents, and restricted cash totaled $299.9 million, which the company believes will be sufficient to fund operations through the completion of its Phase 3 development program.
Looking ahead, Cidara anticipates continued net losses as it invests heavily in the development of CD388. The company is focused on achieving regulatory approvals and commercializing its product candidates, which it views as essential for transitioning to profitable operations. The ongoing clinical trials and strategic partnerships, particularly with BARDA, are critical components of Cidara's strategy to enhance its market position and financial stability in the competitive biotechnology landscape.
About Cidara Therapeutics, Inc.
Cidara Therapeutics is a biotechnology company focused on developing innovative drug-Fc conjugate immunotherapies targeting serious diseases. Its core platform, Cloudbreak, creates long-acting, potent therapies for viral infections like influenza and solid tumors, leveraging dual mechanisms of disease prevention and immune engagement. The company’s key products include CD388 for influenza prophylaxis and CBO421 for cancer, aiming to improve treatment efficacy and resistance profiles through proprietary, targeted biologics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.